BACKGROUND

Immune dysregulation that occurs with coronavirus infection leads to increased resistance of the psoriatic process to routine treatment methods and warrants the study of the features of the clinical course and immunogenesis of psoriasis in patients after COVID-19.

OBJECTIVE

To develop clinical and immunological criteria for the post-COVID course of psoriasis and identify clinical and pathogenetic variants of this dermatosis, considering their most pathognomonic diagnostic signs.

MATERIAL AND METHODS

The study included 125 patients with psoriasis who had COVID-19 during the last year. Testing was conducted using the «Dermatological Quality of Life Index» questionnaire. The cytokine profile, serum/plasma adhesion molecule levels, lytic activity of natural killer cells, endogenous nitric oxide level, and TLR2 and TLR4 expression on peripheral blood monocytes were measured.

RESULTS

According to immunological studies, there are three types of psoriasis characterized by diverse, partly multidirectional immune disorders. Analysis of the results of clinical and immunological studies showed that in type 1, the characteristic clinical manifestations of the disease include psoriasis vulgaris with moderate and severe course, exudative and arthropathic psoriasis. Type 2 includes psoriasis vulgaris of various severity; arthropathic psoriasis and other types are less common. In type 3, clinical manifestations of other psoriasis types and psoriatic onychodystrophy were more often observed.

CONCLUSION

In patients with psoriasis after COVID-19, various immune disorders were observed. The identified clinical and immunological features of the psoriasis course in the post-COVID period will contribute to a more rational and targeted approach to treatment regimens.